Published in Clin Dev Immunol on November 17, 2011
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | NCT01346358
STAT3 Inhibitor for Solid Tumors | NCT00955812
Safety Study of PLX108-01 in Patients With Solid Tumors | NCT01004861
STAT3 DECOY in Head and Neck Cancer | NCT00696176
S0916, MLN1202 in Treating Patients With Bone Metastases | NCT01015560
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers | NCT01316822
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39
M1 and M2 macrophages: the chicken and the egg of immunity. J Innate Immun (2014) 2.06
Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci (2013) 1.50
ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res (2013) 1.32
Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One (2012) 1.18
Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05
Macrophages and chemokines as mediators of angiogenesis. Front Physiol (2013) 0.98
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One (2015) 0.90
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res (2013) 0.89
Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med (2013) 0.88
Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. Br J Cancer (2015) 0.87
Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics (2015) 0.87
Protein kinase C Beta in the tumor microenvironment promotes mammary tumorigenesis. Front Oncol (2014) 0.83
miRNA expression in anaplastic thyroid carcinomas. PLoS One (2014) 0.83
Macrophages at the fork in the road to health or disease. Front Immunol (2015) 0.82
On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment. Exp Cell Res (2013) 0.81
The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients' survival. J Mol Histol (2013) 0.81
Macrophages modulate migration and invasion of human tongue squamous cell carcinoma. PLoS One (2015) 0.81
Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy. Sci Rep (2015) 0.81
Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Oncoimmunology (2015) 0.80
Cycling hypoxia induces a specific amplified inflammatory phenotype in endothelial cells and enhances tumor-promoting inflammation in vivo. Neoplasia (2015) 0.79
Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther (2016) 0.79
Tumor-associated macrophages promote tumor cell proliferation in nasopharyngeal NK/T-cell lymphoma. Int J Clin Exp Pathol (2014) 0.77
The influence of linker length on the properties of cathepsin S cleavable (177)Lu-labeled HPMA copolymers for pancreatic cancer imaging. Biomaterials (2014) 0.77
Harnessing DNA-induced immune responses for improving cancer vaccines. Hum Vaccin Immunother (2012) 0.77
The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. PLoS One (2014) 0.77
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness. Oncotarget (2016) 0.76
Significance of TNF-α and the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma. J Thyroid Res (2016) 0.76
MIRAgel: the immunohistochemical expression of CD3, CD34, and CD68 in the surrounding capsule. Eye (Lond) (2016) 0.75
Increasing the Inflammatory Competence of Macrophages with IL-6 or with Combination of IL-4 and LPS Restrains the Invasiveness of Pancreatic Cancer Cells. J Cancer (2016) 0.75
Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
MicroRNA-720 suppresses M2 macrophage polarization by targeting GATA3. Biosci Rep (2016) 0.75
Tumor-Associated Macrophage (TAM) and Angiogenesis in Human Colon Carcinoma. Open Access Maced J Med Sci (2015) 0.75
Reply: Comment on 'Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma'. Br J Cancer (2013) 0.75
Mutant CCL2 protein coating mitigates wear particle-induced bone loss in a murine continuous polyethylene infusion model. Biomaterials (2016) 0.75
Enhancement of macrophage inflammatory responses by CCL2 is correlated with increased miR-9 expression and downregulation of the ERK1/2 phosphatase Dusp6. Cell Immunol (2017) 0.75
Butylated hydroxyanisole blocks the occurrence of tumor associated macrophages in tobacco smoke carcinogen-induced lung tumorigenesis. Cancers (Basel) (2013) 0.75
M3 Macrophages Stop Division of Tumor Cells In Vitro and Extend Survival of Mice with Ehrlich Ascites Carcinoma. Med Sci Monit Basic Res (2017) 0.75
FXYD5 Protein Has a Pro-inflammatory Role in Epithelial Cells. J Biol Chem (2016) 0.75
Sensitivity of Dendritic Cells to Microenvironment Signals. J Immunol Res (2016) 0.75
Role of liver ICAM-1 in metastasis. Oncol Lett (2017) 0.75
Cancer-related inflammation. Nature (2008) 34.21
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophage activation and polarization. Front Biosci (2008) 11.17
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 6.45
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science (1997) 4.89
The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol (2000) 4.78
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A (2007) 4.24
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res (2000) 3.86
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 3.35
CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell (2011) 3.31
Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol (1999) 3.04
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet (2008) 2.83
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol (2005) 2.81
Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem (1993) 2.61
Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res (2009) 2.61
Biology and action of colony--stimulating factor-1. Mol Reprod Dev (1997) 2.52
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer (2001) 2.51
A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature (1997) 2.44
Differentiation of T regulatory cells by immature dendritic cells. J Exp Med (2001) 2.35
Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst (1991) 2.35
Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep (2005) 2.31
Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol (1998) 2.17
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res (2000) 2.12
Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res (2004) 2.12
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 2.11
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res (2002) 2.09
Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer (2006) 2.09
Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology (2009) 2.05
NF-kappaB as a potential molecular target for cancer therapy. Biofactors (2007) 1.93
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 1.91
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest (1995) 1.91
Adverse effects of bisphosphonates: current issues. J Support Oncol (2008) 1.90
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer (2010) 1.87
A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol (1997) 1.83
Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer (2009) 1.80
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res (2003) 1.78
Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development. Proc Natl Acad Sci U S A (1989) 1.77
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol (2007) 1.75
Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res (2008) 1.73
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res (2010) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol (2007) 1.70
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol (2007) 1.67
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs (2006) 1.63
Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release (2010) 1.63
Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer (2009) 1.62
Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract (1998) 1.60
Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood (2009) 1.59
Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem (2002) 1.55
Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene (2004) 1.54
Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol (1999) 1.52
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol (2010) 1.51
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol (2008) 1.50
Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther (2007) 1.48
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci (2011) 1.46
Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res (2010) 1.46
Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res (2006) 1.41
Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J Biol Chem (1999) 1.41
Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat (2010) 1.40
Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A (2002) 1.40
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep (2003) 1.37
Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res (1997) 1.35
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res (2007) 1.35
The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med (2010) 1.33
Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer (2004) 1.26
Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol (2011) 1.24
Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology (2004) 1.23
The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica (2006) 1.21
Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res (2004) 1.21
Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res (2004) 1.20
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res (2009) 1.20
Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol (1990) 1.18
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate (2010) 1.18
Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol (2009) 1.15
Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol (2010) 1.14
Unique regulation of CCL18 production by maturing dendritic cells. J Immunol (2003) 1.14
Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther (2008) 1.14
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2009) 2.92
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol (2008) 1.91
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res (2008) 1.80
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol (2010) 1.73
Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One (2012) 1.70
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2002) 1.65
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett (2007) 1.61
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol (2010) 1.61
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol (2003) 1.57
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med (2011) 1.55
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer (2007) 1.27
Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One (2010) 1.26
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist (2007) 1.24
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut (2012) 1.19
Re: Plexiform angiomyxoid myofibroblastic tumor of the stomach. Am J Surg Pathol (2008) 1.17
Combined modality therapy of gemcitabine and radiation. Oncologist (2005) 1.17
Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am J Surg Pathol (2007) 1.12
ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2003) 1.12
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer (2010) 1.10
Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum (2009) 1.09
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer (2010) 1.09
Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int J Radiat Oncol Biol Phys (2006) 1.07
Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood (2002) 1.05
Metastasized angiosarcoma of the spleen in a 2-year-old girl. Pediatr Hematol Oncol (2005) 1.02
Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. Cancer Microenviron (2011) 0.99
Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. J Mol Diagn (2008) 0.99
Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol (2014) 0.98
Clinical potential of intravenous neural stem cell delivery for treatment of neuroinflammatory disease in mice? Cell Transplant (2010) 0.98
Molecular analysis of primary gastric cancer, corresponding xenografts, and 2 novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis. Hum Pathol (2007) 0.97
Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol (2012) 0.97
Current challenges for the advancement of neural stem cell biology and transplantation research. Stem Cell Rev (2012) 0.96
Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer (2002) 0.96
Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett (2008) 0.95
Inflammatory myofibroblastic tumor with ALK/TPM3 fusion presenting as ileocolic intussusception: an unusual presentation of an unusual neoplasm. Hum Pathol (2005) 0.94
Digestive oncologist in the gastroenterology training curriculum. World J Gastroenterol (2011) 0.94
Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics (2013) 0.94
Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol (2002) 0.93
Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008. Int J Gynecol Cancer (2012) 0.93
Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis (2010) 0.93
Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med (2008) 0.92
Expression analysis on archival material revisited: isolation and quantification of RNA extracted from FFPE samples. Diagn Mol Pathol (2013) 0.92
Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol (2004) 0.91
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Ann Surg Oncol (2012) 0.91
Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol (2014) 0.91
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? Expert Rev Anticancer Ther (2014) 0.91
The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res (2012) 0.90
An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target Oncol (2013) 0.90
Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53. Radiat Res (2005) 0.90
Krüppel-like factors in cancer progression: three fingers on the steering wheel. Oncotarget (2014) 0.90
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer (2009) 0.90
Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol (2007) 0.89
Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg (2008) 0.89
Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stability. Eur J Pharm Biopharm (2006) 0.89
Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys (2003) 0.89
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest (2008) 0.89
Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer (2004) 0.89
Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist (2013) 0.89
The role of targeted therapy for gastrointestinal tumors. Expert Rev Gastroenterol Hepatol (2014) 0.88
Quantitative and phenotypic analysis of mesenchymal stromal cell graft survival and recognition by microglia and astrocytes in mouse brain. Immunobiology (2012) 0.88
In vivo imaging of apoptosis in oncology: an update. Mol Imaging (2011) 0.88
Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal cancer xenograft model. Mol Imaging (2012) 0.87
Cell type-associated differences in migration, survival, and immunogenicity following grafting in CNS tissue. Cell Transplant (2012) 0.87
Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. BMC Res Notes (2014) 0.87
Recognition of cellular implants by the brain's innate immune system. Immunol Cell Biol (2010) 0.87
Labeling of Luciferase/eGFP-expressing bone marrow-derived stromal cells with fluorescent micron-sized iron oxide particles improves quantitative and qualitative multimodal imaging of cellular grafts in vivo. Mol Imaging Biol (2011) 0.87
Postextubation obstructive pseudomembranes: a case series and review of a rare complication after endotracheal intubation. Lung (2010) 0.86